OM
RLMD icon

Opaleye Management’s Relmada Therapeutics RLMD Stock Holding History

Opaleye Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.47M Hold
935,000
– – 0.59% 31
2026
Q1 		$6.51M Hold
935,000
– – 0.86% 26
2025
Q4 		$4.52M Buy
+935,000
New +$3.13M 0.6% 32
2024
Q4 		– Sell
-480,000
Closed -$1.56M – 48
2024
Q3 		$1.56M Sell
480,000
-120,000
-20% -$389K 0.26% 37
2024
Q2 		$1.8M Sell
600,000
-159,000
-21% -$575K 0.41% 42
2024
Q1 		$3.53M Sell
759,000
-118,000
-13% -$569K 0.77% 33
2023
Q4 		$3.63M Buy
877,000
+847,000
+2,823% +$2.51M 0.97% 25
2023
Q3 		$90K Buy
+30,000
New +$89.1K 0.03% 40

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Opaleye Management's RLMD Position: Q2 2026 in Review

Opaleye Management held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 935,000 shares worth $6.47M. The position accounts for 0.59% of the portfolio, ranked #31.

Opaleye Management first reported a position in RLMD in Q3 2023 and has held it in 8 quarters since. The position peaked at $6.51M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Opaleye Management held 935,000 shares of Relmada Therapeutics worth $6.47M as of Q2 2026.
  • Opaleye Management left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up 0.59% of Opaleye Management's portfolio in Q2 2026, its #31 holding.
  • Opaleye Management first reported a position in Relmada Therapeutics in Q3 2023 and has held it in 8 quarters since.
  • Opaleye Management's Relmada Therapeutics position peaked at $6.51M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.